CAPRIOLI, FLAVIO ANDREA
CAPRIOLI, FLAVIO ANDREA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care
2026 G. Privitera, M. Allocca, L. Antonioli, E. Calabrese, F. Caprioli, F. Castiglione, S. Danese, M. Daperno, G. Dragoni, M.C. Fantini, C. Felice, G. Fiorino, A. Orlando, L. Pradelli, D. Ribaldone, F. Rizzello, E. Savarino, F. Scaldaferri, A. Armuzzi
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
2026 J.P. Gisbert, M. Chaparro, B. Verstockt, P. Kienle, S. Minozzi, M. Allocca, R. Atreya, N. Avellaneda, M. Barreiro-de Acosta, R. Battat, D. Bettenworth, I. Blumenstein, S.R. Brown, J.P. Burke, F. Caprioli, M.J. Casanova, N. Christou, A. De Buck Van Overstraeten, G. Doherty, P. Eder, A. El-Hussuna, P. Ellul, M.C. Fantini, F. Furfaro, T. Greuter, K. Hazel, S. Holubar, C. Kapizioni, U. Kopylov, R.W. Leong, S. Leventoglu, J.K. Limdi, N.M. Noor, I. Papaconstantinou, G. Peros, L. Pouillon, C. Reenaers, S. Saibeni, C. Schmidt, P. Sousa, L.P.S. Stassen, M. Uzzan, S. Vieujean, E. Visser, P. Myrelid, M. Adamina, T. Kucharzik
VSL#3® May Reduce Abdominal Pain and Bloating in Ulcerative Colitis Remission with IBS-like Symptoms: An Exploratory Randomized, Double-Blind Placebo-Controlled Trial
2026 N. Borruel Sainz, X. Serra-Ruiz, F. Guarner Aguilar, F. Castiglione, O. Maria Nardone, L. Laterza, F. Cascella, A. Gasbarrini, A. Dobrowolska, A. Kanikowska, P. Miheller, O. Menyhárt, D. Noviello, F. Caprioli
Preoperative malnutrition is associated with suppressed intratumoral T cell function and distinct tumor-associated microbiota in colorectal cancer: a prospective pilot study
2026 F. Perillo, F. Mascaretti, P. Maragno, C. Amoroso, E. Oriani, A. Baeri, P. Pinco, L. Pozzi, L. Baldari, F. Caprioli, M. Ghidini, F. Strati, F. Facciotti
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
2026 D. Noviello, F. Caprioli, N.M. Noor
A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease
2026 C. Amoroso, F. Strati, P. Maragno, B. Caridi, D. Noviello, M. Gilodi, M. Muià, S. Frazzini, F. Perillo, M. Vecchi, F. Caprioli, F. Facciotti
VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial
2026 C. Amoroso, B. Marinoni, P. Maragno, A. Rimondi, F. Bottaro, C. Ciafardini, M. Muià, I. Honcharyuk, D. Noviello, B. Caridi, E.M. Sommella, A. Bandera, A. Gori, M. Mantero, F. Blasi, R. Ferrucci, A. Priori, F. Strati, M. Vecchi, F. Facciotti, F. Caprioli
Early recognition of peripheral spondyloarthritis in inflammatory bowel disease: A prospective observational study integrating detail questionnaire screening, ultrasound-based diagnosis, and gut microbiota profiling
2026 F. Santagata, M. Ferrito, E.G. Favalli, R. Caporali, O. De Lucia, I. Honcharyuk, E. Panichi, F. Conforti, N.P. O Sed, L. Spina, B. Caridi, G. Trignani, L. Ingrao, M. Vecchi, F. Caprioli
The assessment of multidimensional clinical, biological and patient-reported outcomes to evaluate the efficacy of add-on Lactobacillus rhamnosus GG supplementation in mild ulcerative colitis: a randomized pilot trial
2026 P. Maragno, C. Amoroso, S. Conforti, M. Michelon, I. Honcharyuk, C. Ciafardini, D. Noviello, F. Strati, F. Caprioli, F. Facciotti, M. Vecchi
The long game in ulcerative colitis: mirikizumab's four-year outcomes
2026 D. Noviello, F. Caprioli
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis
2026 G. Privitera, C. Bezzio, G. Figlioli, F. D'Amico, J. Mendes, S. Varca, F. Zingone, I.R. Lago, S. Onali, F.A. Caprioli, M. Chaparro, M.B. Acosta, K. Karmiris, N.T. Degabli, L. Dar, L. Pastorelli, A. Gutiérrez, A. Orlando, Y. Zabana, S. Saibeni, D. Piovani, E.V. Savarino, D. Pugliese, F. Magro, S. Danese, A. Armuzzi, S. Bonovas, F. Fanizzi, P. Ferraz, F. Scaldaferri, B. Barberio, I. Moraleja, A. Favale, D. Noviello, J.P. Gisbert, M. Porto-Silva, A. Psistakis, H. Yanai, U. Kopylov, M. Di Pietro, L. Madero-Velázquez, F.S. Macaluso, R. Orlando, R. Gabbiadini, A.D. Buono, L. Loy, G. Migliorisi, C. Zoratti
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study
2026 F. Scaldaferri, F. Di Vincenzo, M. Aloi, M. Ascolani, P. Balestrieri, L. Bertani, C. Bezzio, G. Bodini, F. Bossa, E. Calabrese, R. Cannatelli, F. Caprioli, M. Cappello, M. Cicala, F. D’Amico, S. Danese, A. De Bernardi, F.R. De Filippo, F. Desideri, D. Di Paolo, A. Di Sario, M.C. Fantini, C. Ferracane, S. Festa, G. Fiorino, R. Gabbiadini, A. Geccherle, V. Gerardi, E. Giangreco, A.G. Gravina, L. Laterza, L.R. Lopetuso, I. Marafini, M. Mastronardi, M. Mendolaro, M. Merli, G. Mocci, S. Onali, M.F. Onidi, L. Pastorelli, A. Piagnani, M.B. Principi, D. Pugliese, D.G. Ribaldone, A. Rispo, F. Rizzello, F. Santagata, E.V. Savarino, R. Spagnuolo, A. Tursi, A. Variola, C. Viganò, A. Armuzzi
Gut microbiome variability and brain structure and function in unipolar and bipolar depression: A review
2026 F. Bottaro, P. Enrico, C. Cabasino, F. Caprioli, P. Brambilla, G. Delvecchio
Pro-inflammatory intestinal Th17-cells are tissue-resident, accumulate in the epithelia in Crohn's disease, and predict unresponsiveness to vedolizumab
2026 M. Paroni, C. Faggiano, C. Righetti, I. Dusetti, V. Ranzani, G. Moschetti, D. Noviello, C. Vasco, M. Vecchi, P. Landini, F. Facciotti, S. Abrignani, F. Caprioli, J. Geginat
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study
2026 G. Privitera, F. Palumbo, F.S. Macaluso, L. Laterza, V. Pardi, A. Viola, D. Noviello, B. Barberio, C. Ricci, P. Balestrieri, M. Cappello, G. Maconi, R. Sablich, A. Variola, R. Bennato, L. Pastorelli, L. Grossi, D.G. Ribaldone, A. Buda, F. Bossa, A. Di Sario, A. Viscido, B. Neri, G. Mocci, C. Pagnini, M.B. Principi, M. Coletta, C. Petruzzellis, S. Mazzuoli, S. Festa, A. Mirarnda, C. Bezzio, L. Fanigliulo, G. Rocco, E.D. Pont, R. Spagnuolo, E.V. Savarino, F.A. Caprioli, W. Fries, L. Ceccarelli, F. Scaldaferri, A. Orlando, A. Testa, D. Pugliese, A. Armuzzi
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
2026 M. Adamina, P. Kienle, M. Chaparro, B. Verstockt, S. Minozzi, M. Allocca, R. Atreya, N. Avellaneda, M. Barreiro-De Acosta, R. Battat, D. Bettenworth, I. Blumenstein, S.R. Brown, J.P. Burke, F. Caprioli, M.J. Casanova, N. Christou, A. De Buck Van Overstraeten, G. Doherty, P. Eder, A. El-Hussuna, P. Ellul, M.C. Fantini, F. Furfaro, T. Greuter, K. Hazel, S. Holubar, C. Kapizioni, U. Kopylov, R.W. Leong, S. Leventoglu, J.K. Limdi, N.M. Noor, I. Papaconstantinou, G. Peros, L. Pouillon, C. Reenaers, S. Saibeni, C. Schmidt, P. Sousa, L.P.S. Stassen, M. Uzzan, S. Vieujean, E. Visser, T. Kucharzik, J.P. Gisbert, P. Myrelid
Evaluating bowel preparation tolerability in IBD: a phase 3 post-hoc comparison of mannitol and PEG-ASC
2025 G.E. Tontini, A. Rimondi, F. Caprioli, G. Aldinio, L. Pastorelli, F. Radaelli, C. Spada, M. Vecchi
AIEC-derived LPS and Outer Membrane Vesicles differently drive the dysregulated immunological pathways linked to Crohn’s Disease
2025 I. Dusetti, F. Facciotti, F. Caprioli, P. Landini, A. Polissi, P. Sperandeo, M. Paroni
Lower Expression of SARS-CoV-2 Host Cell Entry Genes in the Intestinal Mucosa of IBD Patients With Quiescent or Mildly Active Disease
2025 L.F. Pisani, G. Albertini Petroni, G. Crespi, S. Mola, M.L. Annunziata, F.A. Caprioli, C. Porta, L. Pastorelli
Immunoproteasome Inhibition Positively Impacts the Gut-Muscle Axis in Duchenne Muscular Dystrophy
2025 A. Farini, F. Strati, M. Molinaro, D. Mostosi, S. Saccone, L. Tripodi, J. Troisi, A. Landolfi, C. Amoroso, B. Cassani, A. Blanco-Miguez, E. Leonetti, D. Bazzani, M. Bolzan, F. Fortunato, F. Caprioli, F. Facciotti, Y. Torrente